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ABSTRACT
Cancer patients are at risk of developing malnutrition from underlying disease as well as from cancer treatment. Moreover, 
weight loss is considered as a predictive factor for disease progression and shorter survival time. As many as 10–20% of 
patients with cancer die from the results of malnutrition, instead of from the cancer itself. In the case of cancer-related 
malnutrition, it is necessary to quickly implement individualized nutritional support depending on the type and stage of 
the disease, metabolic changes, the patient’s condition, expected survival and the function of the gastrointestinal tract. 
Artificial nutrition reduces the side effects of chemotherapy and improves immunity. Perioperatively it reduces the risk 
of infection, facilitates wound healing and shortens the length of hospitalization, thereby reducing the costs of the treat-
ment. Initially, a malnourished patient, without gastrointestinal dysfunction, qualifies for nutritional counseling. When the 
energy needs cannot be met by normal feeding, nutritional supplements, taken orally, are recommended. The next step 
is to feed the patient by nasogastric tube or percutaneous endoscopic gastrostomy. Parenteral nutrition, which results in 
more side effects, is only started when enteral nutrition is insufficient to ensure adequate nutritional status or in cases of 
gastrointestinal tract obstruction. The benefit of parenteral nutrition is that it especially provides for those patients with 
gynaecological cancer who have radiation-induced intestinal damage and post-surgical complications such as short bowel 
syndrome. Palliative nutrition must to relieve hunger and thirst. Nutritional interventions should be individualized and 
focused on the changing nutrient needs of the patient and should be supported by physical activity. Regular assessment 
of the nutritional status of the patient should be an inherent element of the oncological treatment.
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INTRODUCTION
Cancer patients are at risk of developing malnutrition 
from the underlying disease as well as from the cancer treat-
ment. In addition, weight loss is considered as a predictive 
factor for disease progression and indicates shorter survival 
times. It is known that 10–20% of patients with cancer die 
from the results of malnutrition, instead of from the cancer 
itself [1]. In 2012, studies showed that doctors underestimate 
how malnutrition influences patients’ quality of life and the 
cancer treatment itself [1]. The data shows that 20–70% 
of oncological patients are malnourished and this applies 
more often to older patients; but only 30–60% of patients 
with a high risk of developing malnutrition are treated [2]. 
This is caused by a lack of knowledge of the guidelines for 
nutritional treatment in cancer which are an important 
part of oncological treatment. In Poland, female patients 
suffering from gynecological cancers comprise 11% of all 
patients treated in the Nutritional Centers of Poznan alone. 
These are mainly patients in the terminal stage of the dis-
ease, following several methods of treatment, and when the 
disease is advanced and life expectancy is not long. Only 
one fourth of them is treated, especially with parenteral 
nutrition, for longer than four months. It is necessary to 
make screening tests among all patients with reproduc-
tive organ cancer, in order to estimate the risk of them 
developing malnutrition. This should be done every time 
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a patient is qualified for treatment, and tests should include 
BMI, estimated weight loss, and muscle mass. Blood tests 
should be also considered. The European Society for Clinical 
Nutrition and Metabolism (ESPEN) analysed all the causes 
and effects of malnutrition in cancer patients and have 
provided specific guidelines for such cases [3]. Nutritional 
interventions should be individualized and focused on the 
changing nutrient needs of the patient and on the reduction 
of inflammation marker levels and should be supported by 
physical activity [4]. 
CURRENT STATE OF KNOWLEDGE
Mechanism of malnutrition
Among cancer patients the most frequent causes of 
malnutrition are: loss of appetite, food intolerance, nausea, 
vomiting, symptoms associated with local tumour growth, 
hypoalbuminemia, anaemia, as well as side effects of the 
oncological treatment [5]. Chemotherapy may cause gastro-
intestinal mucositis, mouth ulcerations, secondary haemor-
rhage, diarrhoea, dysgeusia (taste disturbance), and nausea. 
All the above lead to a reduction of food intake and increased 
risk of malnutrition [6]. Similarly, the adverse effects of radio-
therapy mainly affect surrounding tissues, and in patients 
receiving treatment for cervical cancer or endometrial cancer 
these adverse effects are enteritis and malabsorption disor-
der [3, 5]. The tumour itself, causes an increased inflammatory 
response, mediated by IL-6, which plays an important role in 
the development of malnutrition, with catabolic effects [7]. 
Pro-inflammatory cytokines cause malabsorption of nutri-
ents and interfere with the metabolism of carbohydrates, 
fats and proteins, and they affect the central appetite control 
system leading to anorexia. Cytokines also affect hepatic 
overproduction of pro-inflammatory acute phase proteins, 
which leads to the worsening metabolism of anticancer 
drugs and increases their toxicity. Activation of inflamma-
tory factors causes the breakdown of tissues and, as a result, 
weight loss and the reduction of muscle mass [7]. Loss of 
muscle mass is associated with worsened prognosis and 
also occurs in obese people. Among those patients, despite 
having a high BMI, muscle mass loss also occurs, along with 
all the malnutrition consequences [5, 8]. BMI is a less valuable 
indicator, because obesity is becoming a more serious prob-
lem. Doctors need to pay more attention to recent weight 
loss or weight loss within a short period, and to the patient’s 
reduced food intake.
Diagnosis of malnutrition
Weight loss is an important sign of malnutrition [8]. 
Special scales are used to assess the patient’s nutritional sta-
tus. In hospitals, the most common ways to assess nutritional 
status are the nutritional risk score (NRS) (Tab. 1) and the 
subjective global assessment (SGA) of nutritional status [9]. 
Further advanced assessments of nutritional status are 
performed by body composition tests using bioelectrical 
impedance analysis, computer tomography, magnetic reso-
nance imaging, biochemical tests and anthropometrical 
indices, such as measuring the thickness of the skin fold over 
the triceps muscle or the circumference of arm muscles [9]. 
According to ESPEN, malnutrition is diagnosed when the 
patient’s BMI is < 18.5 kg/m2 or when the patient reports 
Table 1. Screening of risk assessment related to malnutrition - NRS 2002 adults (above 18 years of age)
Impaired nutritional status Severity of the disease  ( increase in requirements )
Score = 0 normal nutritional status Score = 0 normal nutritional requirement
Mild Score = 1
weight loss > 5% in 3 months or food intake 
below 50–75% of normal requirement in 
preceding week
Mild Score = 1
e.g. hip fracture, chronic diseases, especially in 
patients with acute complications (eg cirrhosis 
of the liver, COPD), radiotherapy
Moderate Score = 2
weight loss > 5% in 2 months or BMI 18.5–
20.5 + impaired general condition or food 
intake 25–50% of normal requirement in 
preceding week
Moderate Score = 2
major abdominal surgery, stroke, elderly 
patients - long-term treatment, postoperative 
renal failure, chemotherapy
Severe Score = 3
weight loss > 5% in 1 month or 
BMI < 18.5 + impaired general condition or 
food intake = 0–25% of normal requirement in 
preceding week. 
Severe Score = 3 head injury, bone marrow transplantation, intensive care patients
if > 70 years: add 1 to total score above
Score: Score: Total points:
Instructions: 
1. select one appropriate degree of disturbance of the state of nutrition and the severity of the disease  
2. sum points  
Score: 
≥ 3 — indicated nutritional treatment  
< 3 — consider a conservative procedure, repeat the test in a week
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unintentional weight loss (> 10% over an unknown period 
or > 5% over 3 months), and in connection with the patient’s 
BMI (< 20 in patients under 70 years and < 22 in patients 
over 70 years), or with a low fat-free mass index (FFMI) 
of < 15 kg/m2 for women and < 17kg/m2 for men. (Fig. 1). 
We also assess CRP and albumin levels using the Glasgow 
Prognostic Score. We identify the nutrition as inadequate 
when the patient has not eaten for a week or when the 
food intake covers less than 60% of the energy demands 
over 1–2 weeks. A change in appetite is the first symptom 
of being at risk of malnutrition, and normal nutrition does 
not meet the body’s needs in cancer. Nutrition support must 
be introduced gradually to avoid refeeding syndrome, and 
especially for patients with large deficits, because it can lead 
to electrolyte, hormonal and metabolic changes and conse-
quently can cause neurological disorders and cardiological 
complications [10] (Fig. 1).
Consequences of malnutrition
The consequences of malnutrition in oncological pa-
tients are weight loss and muscle mass loss, weakening of 
the immune system, increased frequency of infections, more 
complications and less tolerance to chemotherapy. Malnu-
trition is associated with a greater number of complications 
of chemotherapy and radiotherapy, which may even lead to 
the necessity to stop treatment and reducing its effective-
ness. It has been clearly shown that malnutrition influences 
the faster progression of the disease, higher mortality rates 
and poorer quality of life. The consequences of malnutrition 
are also pain, weakness and depression. Patients with stable 
body weight have a longer survival time [11]. Nutritional 
status is an important predictor of the treatment’s toler-
ance and of increased mortality. Therefore, it is important 
not only to recognize malnutrition, but also to identify and 
monitor patients at risk of its occurrence, in order to start 
early nutritional treatment [12–14]. 
Artificial nutrition
The goal of nutritional treatment in cancer patients is to 
prevent any further deterioration of their nutritional status, 
as well as to support the oncological treatment [15]. It is 
a supportive treatment that improves the patient’s func-
tional ability and overall fitness state, increases the body’s 
immune system, improves tolerance to chemotherapy and 
reduces its side effects. However, in order to achieve the 
desired goals, it must be introduced early enough, and if this 
is achieved, it reduces the risk of infections, enables wound 
healing, shortens hospitalization and reduces the costs of 
treatment. Physical activity is also important and prevents 
loss of muscle mass. Artificial nutrition includes nutrient 
supplements introduced via the gastrointestinal tract (oral 
or enteral) or by intravenous line. (Fig. 1). If an oncological 
patient with an expected survival time longer than several 
months who does not have gastrointestinal dysfunctions, 
is unable to cover their energy demands with a normal diet, 
nutritional treatment is induced. This treatment is based on 
the diagnosis of the type and stage of the disease, its sever-
ity, the type of treatment planned, as well as taking into con-
sideration the individual preferences and general condition 
of the patient. The first step is dietary counselling. If this is 
insufficient, the next step is the introduction of oral nutrition 
supplements followed by feeding the patient by nasogas-
tric tube or percutaneous endoscopic gastrostomy [16]. 
Parenteral nutrition, which has more side effects than the 
abovementioned treatments, is only started when enteral 
nutrition is insufficient to ensure the patient’s adequate 
nutritional status and when malnutrition will shorten the 
survival time compared with the prognosis of death due 
to cancer disease itself. (Fig. 1).
Parenteral nutrition in gynecologic oncology
Around 50% of patients referred from gynaecological 
oncology units for parenteral nutrition treatment are pa-
tients suffering from cervical or endometrial cancer with 
radiation-induced enteritis and secondary malabsorption 
syndrome. Acute radiation-induced enteropathy occurs 
within a few days after the therapy and affects only the 
mucous membrane. The subacute condition occurs during 
the first year after radiotherapy and the mucous and submu-
cous membrane are affected. However, the chronic condi-
tion occurs several years after radiotherapy and affects all 
layers of the intestine wall. The risk of enteropathy increases 
with age, co-morbidities, and after previous surgical proce-
dures. About 80% of patients treated with radiotherapy fo-
cused on their pelvic area experience side effects associated 
with their digestive system and suffer weight loss. About 
20% of them will develop chronic intestinal inflammation 
after radiotherapy. Intestinal failure develops in about 5% 
and this is a group that should be treated with parenteral 
nutrition as they will benefit the most from this type of 
nutrition. Nutritional support, preferably enteral nutrition, 
during the entire treatment of patients with cervical cancer 
and endometrial cancer, will either avoid or reduce side ef-
fects and the interruptions of treatment that are caused by 
the side effects of radiotherapy [17].
The conditions for patients with advanced cancer quali-
fying for parenteral nutrition are: expected overall survival 
time > 3 months, > 50 points in the Karnofsky score and 
no irreversible damage of the liver, kidneys and lung func-
tions. The main indications for parenteral nutrition in gy-
necologic oncology include:
 Ū obstruction of the gastrointestinal tract in advanced, 
metastatic ovarian cancer (secondary dysphagia, when 
enteral nutrition is impossible);
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Figure 1. A brief description of the procedure in the event of suspected malnutrition. PEG-PEJ — percutaneous endoscopic gastrostomy-
percutaneous endoscopic jejunostomy; PEG — percutaneous endoscopic gastrostomy. *Marking 1–2 a week or more often depending on the 
needs and type of disorder. **The most common selected indications in oncological gynecology. ***Referral to a Nutritional Treatment Center
ASSESSMENT OF MALNUTRITION
ONCOLOGICAL PATIENTS
NRS screening scale:
– BMI
– weight loss
– eating disorders
– worsening of the disease
Diagnosis of malnutrition
NRS ≥ 3
Advanced assessment: body composition test
(bioimpedance)*
Assessment of energy demand:
25-35 kcal/ kg / day
– protein 1.5–2 g / kg/ day
– fats 1.3 g / kg / day
– glucose 3 g / kg /day
Evaluation of metabolic status*:
gasometry, morphology, glucose level, albumin,
total protein, urea, creatinine, bilirubin, ALT,
AST, GGTP, ALP, Na, K, Ca, P., Mg, CI, TAG,
cholesterol, Fe, CRP, INR, Urine-test General
Recommended in a
specialist center
Selection of the type of feeding
support
Normal function of gastrointestinal tract
Parenteral nutrition
Indications**:
– the gastrointestinal morbidity
– radiation-induced enteritis
– perioperative
– postoperative complications: short bowel
syndrome
– entero-cutaneous stula
short-term
(in the hospital):
– peripheral access
– central access
Long-term:
(at home)***
– c. Broviac
– c. PICC
– vascular port
Indications**:
– neurological disorders
– oral mucositis in the course of
chemotherapy
Enteral nutrition
(industrial diets);
– Nasogastric tube
– PEG
– PEG-PEJ
– microjejunostomy
Oral nutritional supplements
Dietary counseling
NO YES
insufficient
insufficient
Karnofsky scale> 50 points
Expected survival time > 3 months
insufficient
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 Ū malabsorption syndrome among patients with enteritis 
after radiotherapy (cervical and endometrial cancer);
 Ū post-surgical complications (short-bowel syndrome, 
entero-cutaneous fistulas);
 Ū perioperative nutrition support to reduce the number 
of complications.
Parenteral nutrition can be divided into 2 parts: 
short-term, used in the perioperative period in malnourished 
patients, which reduces perioperative risk and strengthens 
the immunological response; and long-term, used in the 
home environment with patients with chronic gastrointes-
tinal insufficiency. Different types of central venous lines are 
used: Broviac catheter-central venous catheter with subcu-
taneous tunnelling, inserted through the jugular vein, the 
subclavian vein or the femoral vein; PICC catheter-peripher-
ally inserted central catheter, inserted through the cephalic 
vein or through the basilic vein; and ports. However, in the 
case of a port, there is a higher risk of infections compared 
with the former two methods. All three methods mentioned 
above can also be used for administering chemotherapy 
while maintaining the principles of high sterility.
Artificial nutrition in palliative care
Often patients are referred for nutritional treatment too 
late, when they are disqualified from other forms of treat-
ment and cachexia is irreversible. Cachexia is considered 
to be a condition that is resistant to treatment in the last 
stages of life. In palliative care, non-invasive feeding sup-
port, adequate for the patient’s needs, is administered, with 
the goal of improving the patient’s comfort and quality of 
life [18]. Palliative nutrition must relieve hunger and thirst. 
Parenteral nutrition has no proven efficacy in this group of 
patients. Only patients in an otherwise good general condi-
tion who have a gastrointestinal obstruction will gain some 
benefits from this method of nutrition. The psychological 
aspect is also very important. Patients with advanced gy-
naecological cancer complicated by intestinal obstruction 
live for 40–93 days [19]. These patients are often referred 
for parenteral nutrition, but this treatment usually only lasts 
from a few days to several weeks [19]. It should also be re-
membered that, according to ESPEN, parenteral nutrition 
is associated with a greater risk of side effects, which occur 
in 4–54% of patients, including: infections associated with 
the feeding port, deep vein thrombosis, deterioration of 
liver functions, worsening organ failure, and reduced quality 
and comfort of life through increasing amounts of effusion 
fluids in patients with ascites or pleural effusion.
SUMMARY
Cancer patients are at risk of developing malnutrition 
from the underlying disease as well as from their cancer 
treatment. Malnutrition increases the number of side ef-
fects of chemotherapy and shortens patient survival time. 
The main goals of artificial nutrition, whether oral, enteral 
or parenteral, are to prevent further weight loss, improve 
muscle strength, restore lost tissues and subsequently cause 
weight gain. The benefit of parenteral nutrition is that it 
especially provides for patients who have radiation-induced 
intestinal damage and post-surgical short bowel syndrome. 
Palliative nutrition must relieve hunger and thirst. Regular 
assessment of the nutritional status of the patient should be 
an inherent element of the oncological treatment.
Conflicts of Interest
The authors declare that there are no conflicts of interest.
Contributions of Authors
We confirm that all the co-authors have been included, have 
contributed to the final manuscript and have approved it. 
MS and EG designed the study, analyzed the data, wrote the 
manuscript and prepared figures for this manuscript. ENM 
and KM critically reviewed the manuscript. 
REFERENCES
1. Gyan E, Raynard B, Durand JP, et al. NutriCancer2012 Investigator Group, 
NutriCancer2012 Investigator Group. Malnutrition in Patients With Can-
cer. JPEN J Parenter Enteral Nutr. 2017 [Epub ahead of print]; 42(1): 255–
260, doi: 10.1177/0148607116688881, indexed in Pubmed: 28135422.
2. Pressoir M, Desné S, Berchery D, et al. Prevalence, risk factors and clinical 
implications of malnutrition in French Comprehensive Cancer Centres. 
Br J Cancer. 2010; 102(6): 966–971, doi: 10.1038/sj.bjc.6605578, indexed 
in Pubmed: 20160725.
3. Arends J, Baracos V, Bertz H, et al. ESPEN expert group recommenda-
tions for action against cancer-related malnutrition. Clin Nutr. 2017; 
36(5): 1187–1196, doi:  10.1016/j.clnu.2017.06.017, indexed in Pub-
med: 28689670.
4. Lacau St Guily J, Bouvard É, Raynard B, et al. NutriCancer: A French ob-
servational multicentre cross-sectional study of malnutrition in elderly 
patients with cancer. J Geriatr Oncol. 2018; 9(1): 74–80, doi: 10.1016/j.
jgo.2017.08.003, indexed in Pubmed: 28888553.
5. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutri-
tion in cancer patients. Clin Nutr. 2017; 36(1): 11–48, doi: 10.1016/j.
clnu.2016.07.015, indexed in Pubmed: 27637832.
6. Wong PW, Enriquez A, Barrera R. Nutritional support in critically ill 
patients with cancer. Crit Care Clin. 2001; 17(3): 743–767, indexed in 
Pubmed: 11525056.
7. Laird BJ, McMillan DC, Fayers P, et al. The systemic inflammatory response 
and its relationship to pain and other symptoms in advanced cancer. On-
cologist. 2013; 18(9): 1050–1055, doi: 10.1634/theoncologist.2013-0120, 
indexed in Pubmed: 23966223.
8. Johns N, Stephens NA, Fearon KCH. Muscle wasting in cancer. Int 
J Biochem Cell Biol. 2013; 45(10): 2215–2229, doi:  10.1016/j.bio-
cel.2013.05.032, indexed in Pubmed: 23770121.
9. Kondrup J, Allison SP, Elia M, et al. Educational and Clinical Practice Com-
mittee, European Society of Parenteral and Enteral Nutrition (ESPEN). 
ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003; 22(4): 
415–421, indexed in Pubmed: 12880610.
10. Aaldriks AbA, van der Geest LGM, Giltay EJ, et al. Frailty and malnutrition 
predictive of mortality risk in older patients with advanced colorectal 
cancer receiving chemotherapy. J Geriatr Oncol. 2013; 4(3): 218–226, 
doi: 10.1016/j.jgo.2013.04.001, indexed in Pubmed: 24070460.
11. Fearon K, Arends J, Baracos V. Understanding the mechanisms and 
treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013; 10(2): 
90–99, doi: 10.1038/nrclinonc.2012.209, indexed in Pubmed: 23207794.
12. Lach K, Peterson SJ. Nutrition Support for Critically Ill Patients With Cancer. 
Nutr Clin Pract. 2017; 32(5): 578–586, doi: 10.1177/0884533617712488, 
indexed in Pubmed: 28633000.
172
Ginekologia Polska 2019, vol. 90, no. 3
www. journals.viamedica.pl/ginekologia_polska
13. Lembeck ME, Pameijer CR, Westcott AM. The Role of Intravenous 
Fluids and Enteral or Parenteral Nutrition in Patients with Life-limiting 
Illness. Med Clin North Am. 2016; 100(5): 1131–1141, doi:  10.1016/j.
mcna.2016.04.019, indexed in Pubmed: 27542432.
14. Cotogni P. Enteral versus parenteral nutrition in cancer patients: evidenc-
es and controversies. Ann Palliat Med. 2016; 5(1): 42–49, doi: 10.3978/j.
issn.2224-5820.2016.01.05, indexed in Pubmed: 26841814.
15. Chow R, Bruera E, Chiu L, et al. Enteral and parenteral nutrition in can-
cer patients: a systematic review and meta-analysis. Ann Palliat Med. 
2016; 5(1): 30–41, doi:  10.3978/j.issn.2224-5820.2016.01.01, indexed 
in Pubmed: 26841813.
16. Orrevall Y. Parenteral nutrition in the elderly cancer patient. Nutrition. 
2015; 31(4): 610–611, doi: 10.1016/j.nut.2014.11.006.
17. Henson CC, Burden S, Davidson SE, et al. Nutritional interven-
tions for reducing gastrointestinal toxicity in adults undergoing 
radical pelvic radiotherapy. Cochrane Database Syst Rev. 2013(11): 
CD009896, doi:  10.1002/14651858.CD009896.pub2, indexed in 
Pubmed: 24282062.
18. Dev R, Dalal S, Bruera E. Is there a role for parenteral nutrition or 
hydration at the end of life? Curr Opin Support Palliat Care. 2012; 
6(3): 365–370, doi:  10.1097/SPC.0b013e328356ab4a, indexed in 
Pubmed: 22801468.
19. Prevost V, Grach MC. Nutritional support and quality of life in cancer 
patients undergoing palliative care. Eur J Cancer Care (Engl). 2012; 
21(5): 581–590, doi:  10.1111/j.1365-2354.2012.01363.x, indexed in 
Pubmed: 22574646.
